Overview

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in Europe. The purpose of the trial is to assess safety, tolerability and pharmacokinetics (the exposure of the trial drug in the body) of liraglutide in obese adolescent subjects aged 12 to 17 years.

Phase:

Phase 1

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Liraglutide